Marinus Pharmaceuticals Inc. (MRNS) NASDAQ
$1.44 - (-)
Market Cap: $79.10M
As of 04/24/24 04:00 PM EDT. Market closed.
Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ
$1.44
- (-)
Market Cap: $79.10M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO Compensation (Base)
$520,000
CEO Compensation (Total)
$725,000
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
142
CEO Compensation (Base)
$520,000
CEO Compensation (Total)
$725,000
Address
.
PRICE CHART FOR MARINUS PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$1.44
Days Range
$1.40 - $1.46
52 week range
$1.11 - $11.26
Volume
1,277,390
Avg. Volume (30 days)
4,537,412
Market Cap
$79.10M
Dividend Yield
-
P/E
(0.56)
Shares Outstanding
54,931,042
Open
-
Previous Close
$1.44
Days Range
$1.40 - $1.46
52 week range
$1.11 - $11.26
Volume
1,277,390
Avg. Volume (30 days)
4,537,412
Market Cap
$79.10M
Dividend Yield
-
P/E
(0.56)
Shares Outstanding
54,931,042
FINANCIAL STATEMENTS FOR MARINUS PHARMACEUTICALS INC
LOADING...
INSIDER TRANSACTIONS FOR MARINUS PHARMACEUTICALS INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Braunstein Scott | CHAIRMAN AND CEO | Mar 27, 2024 | Option Exercise | $4.28 | 50,000 | 214,000 | 273,512 | Mar 27, 2024, 11:55 AM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Feb 20, 2024 | Sale | $9.56 | 2,153 | 20,583 | 60,308 | Feb 22, 2024, 04:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Feb 16, 2024 | Sale | $9.98 | 2,814 | 28,084 | 66,635 | Feb 21, 2024, 04:06 PM |
Braunstein Scott | CHAIRMAN AND CEO | Feb 16, 2024 | Sale | $9.94 | 11,850 | 117,789 | 223,512 | Feb 21, 2024, 04:05 PM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Aug 08, 2023 | Sale | $8.93 | 11 | 98 | 40,626 | Aug 08, 2023, 09:05 PM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Aug 07, 2023 | Sale | $9.52 | 2,385 | 22,705 | 40,637 | Aug 08, 2023, 09:05 PM |
Braunstein Scott | CHAIRMAN AND CEO | Aug 08, 2023 | Sale | $8.94 | 30 | 268 | 160,762 | Aug 08, 2023, 09:05 PM |
Braunstein Scott | CHAIRMAN AND CEO | Aug 07, 2023 | Sale | $9.55 | 6,413 | 61,244 | 160,792 | Aug 08, 2023, 09:05 PM |
Pfanstiel Steven | CFO AND COO | Aug 08, 2023 | Sale | $8.93 | 14 | 125 | 49,324 | Aug 08, 2023, 09:05 PM |
Pfanstiel Steven | CFO AND COO | Aug 07, 2023 | Sale | $9.54 | 2,790 | 26,617 | 49,338 | Aug 08, 2023, 09:05 PM |
MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. | Aug 07, 2023 | Sale | $9.54 | 2,169 | 20,692 | 33,036 | Aug 08, 2023, 09:05 PM |
MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. | Aug 08, 2023 | Sale | $8.93 | 11 | 98 | 33,025 | Aug 08, 2023, 09:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Aug 08, 2023 | Sale | $8.93 | 13 | 116 | 47,614 | Aug 08, 2023, 09:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Aug 07, 2023 | Sale | $9.55 | 2,889 | 27,590 | 47,627 | Aug 08, 2023, 09:05 PM |
Fischer Seth H. Z. | Director | Feb 06, 2023 | Sale | $6.54 | 1,018 | 6,658 | 6,026 | Feb 08, 2023, 04:37 PM |
Ezickson Elan | Director | Feb 06, 2023 | Sale | $6.56 | 750 | 4,920 | 5,600 | Feb 08, 2023, 04:36 PM |
Austin Charles | Director | Feb 06, 2023 | Sale | $6.49 | 1,073 | 6,964 | 5,277 | Feb 08, 2023, 04:36 PM |
Shafer Christina | Chief Commercial Officer | Nov 09, 2022 | Option Exercise | $4.70 | 1,505 | 7,073 | 25,647 | Nov 14, 2022, 07:43 AM |
VITULLO NICOLE | Director | Mar 15, 2021 | Sale | $15.87 | 4,250 | 67,447 | 0 | Mar 16, 2021, 04:58 PM |
Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Option Exercise | $4.16 | 35,927 | 149,456 | 53,644 | Mar 11, 2021, 04:04 PM |
Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Sale | $17.80 | 40,356 | 718,337 | 13,288 | Mar 11, 2021, 04:04 PM |
Smith Edward F | CFO | Jan 30, 2020 | Sale | $2.05 | 2,380 | 4,879 | 17,717 | Feb 03, 2020, 06:29 PM |
Braunstein Scott | Chief Executive Officer | Dec 13, 2019 | Buy | $1.25 | 100,000 | 125,000 | 100,000 | Dec 13, 2019, 04:08 PM |
Smith Edward F | CFO | May 16, 2019 | Sale | $5.03 | 24,211 | 121,781 | 20,097 | May 20, 2019, 04:20 PM |
Cashman Christopher Michael | CEO | Mar 18, 2019 | Option Exercise | $1.04 | 31,662 | 32,928 | 271,423 | Mar 20, 2019, 05:57 PM |
Cashman Christopher Michael | CEO | Jan 28, 2019 | Sale | $3.13 | 8,142 | 25,484 | 239,761 | Jan 30, 2019, 04:09 PM |
Smith Edward F | CFO | Jan 29, 2019 | Sale | $3.06 | 2,492 | 7,626 | 44,308 | Jan 30, 2019, 04:08 PM |
Smith Edward F | CFO | Jan 29, 2018 | Sale | $7.91 | 3,000 | 23,730 | 49,800 | Jan 29, 2018, 08:00 PM |
Cashman Christopher Michael | CEO | Jan 18, 2018 | Sale | $6.28 | 9,566 | 60,074 | 247,903 | Jan 22, 2018, 08:41 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 19, 2017 | Sale | $7.43 | 150,000 | 1,114,670 | 4,032,682 | Dec 19, 2017, 08:30 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 18, 2017 | Sale | $7.50 | 300,000 | 2,251,440 | 4,127,453 | Dec 19, 2017, 08:30 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 15, 2017 | Sale | $8.10 | 822,547 | 6,658,691 | 4,530,335 | Dec 19, 2017, 08:30 PM |
Mehra Anand | 10% Owner | Oct 20, 2016 | Sale | $1.39 | 750,683 | 1,042,699 | 1,134,851 | Oct 24, 2016, 04:49 PM |
Canaan VII LP | 10% Owner | Aug 08, 2016 | Sale | $1.50 | 19,950 | 29,925 | 1,850,783 | Aug 09, 2016, 10:03 AM |
Canaan VII LP | 10% Owner | Aug 05, 2016 | Sale | $1.50 | 129,204 | 193,806 | 1,870,733 | Aug 09, 2016, 10:03 AM |
Canaan VII LP | 10% Owner | Aug 04, 2016 | Sale | $1.50 | 3,329 | 4,994 | 1,999,937 | Aug 05, 2016, 10:18 AM |
Canaan VII LP | 10% Owner | Aug 03, 2016 | Sale | $1.50 | 142,254 | 213,381 | 2,003,266 | Aug 05, 2016, 10:18 AM |
Canaan VII LP | 10% Owner | Jul 29, 2016 | Sale | $1.71 | 24,540 | 41,963 | 2,145,520 | Aug 02, 2016, 12:22 PM |
Canaan VII LP | 10% Owner | Jul 27, 2016 | Sale | $1.80 | 209 | 376 | 2,170,060 | Jul 27, 2016, 04:30 PM |
Canaan VII LP | 10% Owner | Jul 26, 2016 | Sale | $1.81 | 20,380 | 36,888 | 2,170,269 | Jul 27, 2016, 04:30 PM |
Canaan VII LP | 10% Owner | Jul 22, 2016 | Sale | $1.94 | 133,133 | 258,278 | 2,328,266 | Jul 26, 2016, 10:08 AM |
Canaan VII LP | 10% Owner | Jul 25, 2016 | Sale | $1.86 | 137,617 | 255,968 | 2,190,649 | Jul 26, 2016, 10:08 AM |
Cashman Christopher Michael | President and CEO | Feb 09, 2016 | Option Exercise | $1.04 | 24,684 | 25,671 | 140,769 | Feb 11, 2016, 05:17 PM |
Cashman Christopher Michael | President and CEO | Nov 06, 2015 | Buy | $5.61 | 3,561 | 19,977 | 116,085 | Feb 11, 2016, 05:17 PM |
Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Feb 04, 2016, 06:48 PM |
Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Sep 28, 2015, 08:12 PM |
MAYLEBEN TIMOTHY M | Director | Jul 16, 2015 | Option Exercise | $1.04 | 42,550 | 44,252 | 42,550 | Jul 17, 2015, 04:01 PM |
Cashman Christopher Michael | President and CEO | Jul 01, 2015 | Option Exercise | $1.04 | 14,086 | 14,649 | 112,524 | Jul 02, 2015, 04:08 PM |
Bloch Stephen M | Director | Jun 10, 2015 | Option Exercise | $1.04 | 3,000 | 3,120 | 3,000 | Jun 11, 2015, 05:26 PM |
Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Option Exercise | $1.04 | 30,000 | 31,200 | 30,000 | Apr 23, 2015, 04:48 PM |
Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Sale | $9.48 | 30,000 | 284,511 | 0 | Apr 23, 2015, 04:48 PM |
Cashman Christopher Michael | PRESIDENT AND CEO | Mar 06, 2015 | Option Exercise | $1.04 | 17,608 | 18,312 | 98,438 | Mar 10, 2015, 01:16 PM |
Cashman Christopher Michael | PRESIDENT AND CEO | Oct 08, 2014 | Option Exercise | $1.04 | 80,830 | 84,063 | 80,830 | Oct 09, 2014, 04:05 PM |
Domain Partners VI, L.P. | 10% Owner | Aug 05, 2014 | Buy | $8.00 | 419,744 | 3,357,952 | 2,476,886 | Aug 07, 2014, 03:06 PM |
Mehra Anand | Director | Aug 05, 2014 | Buy | $8.00 | 750,683 | 6,005,464 | 1,859,639 | Aug 07, 2014, 12:43 PM |
Canaan VII L P | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
Bloch Stephen M | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Load More Insider Transactions
FUNDS WITH A POSITION IN MARINUS PHARMACEUTICALS INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,346,119 | 2.63% | 2.71% | Growth At A Reasonable Price |
BLACKROCK INC. | 4,599,278 | 0.00127% | 10.94% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,581,250 | 0.06% | -11.13% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,139,494 | 0.0013% | 9.05% | Other |
AQR CAPITAL MANAGEMENT LLC | 23,024 | 0.00047% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR MARINUS PHARMACEUTICALS INC
STOCK BUYBACKS FOR MARINUS PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
5.19%
1Q
06/30/2023
7.93%
2Q
03/31/2023
9.56%
3Q
12/31/2022
37.98%
4Q
09/30/2022
49.62%
5Q
06/30/2022
52.66%
6Q
03/31/2022
53.75%
7Q
12/31/2021
54.19%
8Q
09/30/2021
54.36%
9Q
06/30/2021
54.72%
10Q
03/31/2021
54.98%
11Q
12/31/2020
78.00%
12Q
09/30/2020
85.65%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR MARINUS PHARMACEUTICALS INC
LOADING...